In this regard, the expression levels of ESR1/ERα-targeting miRNAs, such as miR-221/222 [8], miR-18a [82], miR-19a/b [83], and miR-22 [9], may predict the clinical responsiveness of ER+ breast cancer patients to tamoxifen. This evidence concerns the gene ESR1 and breast carcinoma.